{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:12Z","timestamp":1791260172200,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Isavuconazole is a triazole antifungal available in IV and capsule formulation. Prescribing information states that capsules should not be chewed, crushed, dissolved or opened because the drug was not studied in this manner. However, considering the pharmacokinetics of the capsules, we theorized opening and sprinkling the contents into an enteral feeding tube (EFT) would result in adequate absorption and systemic concentrations of isavuconazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine whether patients receiving isavuconazonium sulphate capsules via EFT would achieve clinical blood concentrations of isavuconazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Nineteen solid organ and HCT recipients receiving isavuconazole via EFT for prevention or treatment of invasive fungal infection (IFI) were prospectively identified at four academic medical centres in the USA. Patients were included in this evaluation if they received isavuconazole via EFT for at least 5\u2009days and therapeutic drug monitoring (TDM) was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>TDM was performed after a median of 7\u2009days (range 6\u201317) following EFT administration and 15\u2009days (range 7\u2013174) of isavuconazole therapy overall. Median isavuconazole concentration was 1.8\u2009\u03bcg\/mL (range 0.3\u20135.2). Median isavuconazole concentrations in patients with or without prior IV administration were 1.8\u2009\u03bcg\/mL (range 0.3\u20135.2) and 2.2\u2009\u03bcg\/mL (range 0.8\u20133.6; P\u2009=\u20090.896), respectively. Concentrations achieved with the EFT route were similar to or greater than the corresponding concentrations via the IV route in six patients who had TDM performed during both routes of administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>It is reasonable to consider opening isavuconazonium sulphate capsules and administering the contents enterally for prevention and treatment of IFI.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa274","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T03:27:40Z","timestamp":1591673260000},"page":"3023-3028","source":"Crossref","is-referenced-by-count":21,"title":["Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-2225","authenticated-orcid":false,"given":"Erin K","family":"McCreary","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Hong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Los Angeles Ronald Reagan Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Borlagdan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M","family":"Rivosecchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel V","family":"Marini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M","family":"Sacha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda P","family":"Silveira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Andes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J","family":"Lepak","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"2021010209295442700_dkaa274-B1","year":"2015"},{"key":"2021010209295442700_dkaa274-B2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.376","article-title":"Two Phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14C-labeled isavuconazonium sulfate in healthy male volunteers","volume":"7","author":"Townsend","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2021010209295442700_dkaa274-B3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2021010209295442700_dkaa274-B4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2021010209295442700_dkaa274-B5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2021010209295442700_dkaa274-B6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021010209295442700_dkaa274-B7"},{"key":"2021010209295442700_dkaa274-B8","doi-asserted-by":"crossref","first-page":"e01728","DOI":"10.1128\/AAC.01728-19","article-title":"Population pharmacokinetics of intravenous isavuconazole in solid organ transplant recipients","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021010209295442700_dkaa274-B9","doi-asserted-by":"crossref","first-page":"e13048","DOI":"10.1111\/tid.13048","article-title":"Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: a case report","volume":"21","author":"Adamsick","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2021010209295442700_dkaa274-B10","doi-asserted-by":"crossref","first-page":"e01034","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021010209295442700_dkaa274-B11","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021010209295442700_dkaa274-B12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/cid\/ciy260","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting?","volume":"67","author":"Fung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021010209295442700_dkaa274-B13","first-page":"1610","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021010209295442700_dkaa274-B14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic-cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021010209295442700_dkaa274-B15","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021010209295442700_dkaa274-B16","doi-asserted-by":"crossref","first-page":"e01783","DOI":"10.1128\/AAC.01783-19","article-title":"Isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation: a case-series and literature review","volume":"64","author":"Decembrino","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021010209295442700_dkaa274-B17","doi-asserted-by":"crossref","first-page":"e00101","DOI":"10.1128\/AAC.00101-17","article-title":"Impact of mucositis on absorption and systemic drug exposure of isavuconazole","volume":"61","author":"Kovanda","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021010209295442700_dkaa274-B18","first-page":"01085","article-title":"Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021010209295442700_dkaa274-B19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/phar.2348","article-title":"Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation","volume":"40","author":"Zhao","year":"2020","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/3023\/35350263\/dkaa274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/3023\/35350263\/dkaa274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T06:45:00Z","timestamp":1666853100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/10\/3023\/5876155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,25]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa274","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,7,25]]}}}